Omada Health (OMDA) Q1 2026 earnings review
Milestone Quarter Eclipsed by Severe Concentration Risk
Omada Health delivered a strong Q1 2026 on the surface, crossing the 1 million total member mark (up 51% YoY) and growing revenue 42% YoY to $78 million. The company successfully executed strategic partnerships with Optum Rx and Eli Lilly, expanding its grip on the GLP-1 care management space. As a result, management raised full-year guidance for both top and bottom lines. However, profitability retreated sequentially—adjusted EBITDA fell to $1 million from Q4's peak of $8.5 million—reflecting telegraphed seasonal enrollment costs. More alarmingly, the quality of revenue is highly questionable: 65% of Q1 sales came from a single related party, a massive structural risk that overshadows the headline growth narrative.
🐂 Bull Case
Crossing 1.02 million members validates Omada's virtual-first, multi-condition strategy. Growth remains robust at 51% YoY, proving high demand beyond point solutions.
By joining Optum Rx's Weight Engage and Eli Lilly's Employer Connect, Omada is now integrated with the nation's three leading PBMs, securing an entrenched position as a 'GLP-1 value maximizer' for employers.
🐻 Bear Case
Related-party revenue accounted for a staggering $51.1 million of Q1's $78 million total sales (65%). This creates an existential dependency on a single entity for the majority of the company's growth.
Adjusted EBITDA margin collapsed from 11.2% in 25Q4 to just 1.3% in 26Q1. Even with seasonality expected, achieving the full-year target relies heavily on aggressive back-half margin expansion.
⚖️ Verdict: ⚪
Neutral. The operational execution, strategic PBM integrations, and raised guidance are excellent. However, an investment thesis cannot ignore that two-thirds of revenue flows from one related-party partner. Until Omada diversifies its revenue base, the stock carries heavy structural risk.
Key Themes
The Growth Illusion: Extreme Related-Party Reliance
Management continues to tout broad-based commercial success and diverse channel growth, but the financials contradict this narrative. In Q1 2026, $51.1 million of the $78.0 million total revenue (65%) was derived from a single related party. This is an acceleration in concentration compared to Q1 2025, where the related party accounted for 60% of revenue ($33.3M of $55.0M). This extreme concentration represents a single point of failure for the business model.
Securing the GLP-1 Macro Tailwinds
As employers grapple with the macroeconomic impact of surging anti-obesity medication costs, Omada has strategically positioned itself as the gatekeeper and companion platform. The addition to Optum Rx's Weight Engage portfolio and Eli Lilly's Employer Connect program in Q1 means Omada now has relationships with the three dominant PBMs that process 80% of US prescription claims. This is a massive driver for top-of-funnel member acquisition.
Q1 Seasonality Masks Core Profitability
As telegraphed in the prior quarter, Q1 acts as the primary enrollment period, carrying the burden of heavy device shipments (hardware cost of revenue jumped to $14.9M) and care team onboarding. Consequently, gross margin dipped from 70.8% in Q4 to 62% in Q1, and adjusted EBITDA fell from $8.5M to $1M. This is a stable, expected pattern, but places high execution pressure on sequential margin expansion through the rest of the year.
Member Base Hits Critical Mass
Total members surged 51% YoY to 1.02 million. Management previously noted that growth is broad-based across diabetes and hypertension programs—not strictly weight health. This scale drives operating leverage over fixed costs and makes Omada an increasingly indispensable platform for health plans aiming to consolidate point solutions.
AI-Driven Engagement Tools Bolstering Outcomes
Omada continues to leverage its proprietary dataset to drive efficiencies. The deployment of AI tools like 'OmadaSpark' (for care team efficiency and real-time motivational interviewing) and 'Meal Map' (for nutrition tracking) are paying dividends. Management previously noted these tools increase user food tracking—a leading indicator for retention and better clinical outcomes, which ultimately protects Omada's renewal rates.
Decelerating Revenue Growth Profile
While 42% YoY growth in Q1 is objectively strong, it represents a deceleration from FY25's 53% pace and Q4's 58% exit rate. Furthermore, the raised FY26 guidance (25% growth at the midpoint) implies that quarterly YoY growth rates will continue to step down significantly as the year progresses. The core business is normalizing.
Intense Cash Burn from Operating Activities
Despite achieving positive Adjusted EBITDA, Omada consumed $11.8M in operating cash flow and generated a negative Free Cash Flow of $13.4M in Q1. While cash reserves remain robust at $211.8M, the disparity between EBITDA and cash flow reflects heavy working capital needs, particularly in accounts receivable and deferred commissions tied to Q1's enrollment spike.
Other KPIs
Improved structurally from 60.0% a year ago, but down sequentially from 70.8% in Q4 2025. This reflects the seasonal burden of hardware shipments for new member onboarding in Q1. Management remains committed to long-term targets of 70%+ annualized gross margins.
Up 54% YoY, mirroring the 51% surge in new member enrollments. Hardware operates as a loss leader to capture services revenue, evidenced by the $14.9 million cost of hardware revenue resulting in a negative hardware gross margin.
Guidance
Decelerating vs historicals, but accelerating against prior expectations. Management raised the range from the previous $312M-$322M. The $326M midpoint implies 25% YoY growth, a notable step down from 2025's 53% growth. This suggests the 42% growth seen in Q1 will cool significantly in the back half of the year.
Accelerating. Raised from the prior outlook of $7M-$15M. The $17M midpoint represents a nearly three-fold increase compared to FY25 ($6.5M). Given the $1M generated in Q1, the guidance implies a steep, profitable ramp generating ~$5.3M per quarter for the remainder of the year.
Key Questions
Related Party Revenue Strategy
With 65% of Q1 revenue tied to a single related party, what is the strategic roadmap for diversifying the customer base, and are there any impending renewal risks associated with this specific contract?
Flex Care and Prescribing Revenue Contribution
Management previously stated that 2026 guidance assumes no meaningful contribution from the newly launched GLP-1 prescribing and Flex Care offerings. Given the guidance raise, have these products started to contribute, or is the raise driven entirely by the core base?
Cash Flow Dynamics vs EBITDA
Q1 adjusted EBITDA was positive, but operating cash flow burned $11.8 million. How should we model the working capital conversion cycle for the remainder of the year to achieve free cash flow positivity?